ABSTRACT. Determining the interaction partners of small molecules in the intact cellular context remains a key challenge in drug research. Thermal proteome profiling (TPP) addresses this need by inferring target engagement from changes in temperature-dependent protein denaturation at a proteome-wide scale. Existing approaches to TPP data analysis have been centered around a single parameter, the melting point. Target engagement is then identified from a compound induced change in this parameter. However, for a substantial number of proteins the melting point shift does not reflect the treatment effect well, or cannot be confidently estimated at all. To overcome these limitations, we present a non-parametric analysis of response curves (NPARC), a functional approach that compares entire curves instead of summary parameters. NPARC projects the data to a space of smooth functions and infers treatment effects by an F-statistic with degrees of freedom estimated from the data. We show
spectrometry with the cellular thermal shift assay (CETSA) [7] , which identifies binding events as shifts in protein thermostability (see Fig. S1 for a detailed explanation). A typical TPP experiment generates temperature dependent abundance measurements for a large fraction of the cellular proteome. Drug binding events can then be inferred from comparing the melting curves of samples with drug versus vehicle (negative control without drug) treatment.
TPP has been successfully applied to identify previously unknown protein-ligand interactions [5] , protein complexes [8] , and downstream effects of drug binding in signaling networks [6, 9, 10, 11] in human cells, but has recently also been extended to bacteria [12] . There is an increasing interest in the technology, including both its experimental and data analytic aspects, in order to identify relevant proteins in the data and their interactions in the living system [13, 14, 15, 16] .
From the data-analysis perspective, the typical goal of a TPP experiment is to quantify the evidence for changes in thermostability. The present statistical workflow [5, 6, 17, 18] fits sigmoid melting curves to temperature-dependent concentrations for each protein. The fitted curves imply estimates of the melting point (T m ), and this single number summary is used to test for differences between control and treatment conditions (Fig. 1A ) [6] . We refer to this published strategy as 'the T m -based approach'. While this approach is intuitive and the estimated T m -shifts yield a readily interpretable output, we show that it leads to a needless loss of sensitivity when applied in the high-throughput setting of TPP.
The main reasons for this sensitivity loss are two-fold: First, drug induced effects on thermostability are not always reflected by shifts in the fitted T m (Fig. 1B-C) . Second, some T m values lie outside of the measured temperature range, which impairs their estimation (Fig. 1D ). Both scenarios can result in important targets being missed in the analysis (Fig. 1E) .
Furthermore, the z-test used in the T m -based approach does not incorporate the goodness-of-fit of the sigmoid model into the test statistic. However, such an assessment is important because of the possibility that a protein does not meet the modeling assumptions of sigmoid curve shape in the cellular environment. To reduce the risk of false discoveries related to such proteins, Savitski et al. [5] had employed a priori filters on the melting curve shape of each protein prior to computing the test statistic (Table 4) . A comparison of the effects of these filters on five published experiments revealed that they discarded between 14-27% of all proteins in each dataset (Fig.   1E ), a significant reduction in the 'testable' part of the proteome (Fig. S2 ).
Here, we overcome these limitations through a nonparametric analysis of response curves (NPARC), which is independent of T m estimation. NPARC applies concepts from functional data analysis by approximating the data generating function underlying the measurements and by performing hypothesis testing based on the fitted functions instead of individual parameter estimates. This offers a twofold benefit compared to the present methodology. First, we test on differences in curves rather than differences in T m , thereby using more information directly rather than first lossfully compressing it into a single variable. Second, the model is more robust against deviations from the expected sigmoid shape. Thus, we increase the coverage of the proteome, including biologically and pharmaceutically relevant proteins. Because melting behavior can be modeled without imposing any specific curve shape a priori, the model could also in principle be adapted to more complex melting curves [19, 20, 21] .
We perform statistical assessment of the improvements in goodness-of-fit by an F-statistic. Other types of test statistics exist in functional data analysis applications and would be possible in this scenario. For example, Maldonado et al. [22] use the sample correlation coefficient between curves and combine it with permutation tests, Storey et al. use an F-like statistic (omitting scaling by degrees of freedom) [23] , and Berck et al. derive a moderated t-statistic in combination with smoothing-spline mixed-effects-models [20] . All these approaches share the problem that the null distribution is not analytically tractable in curve data that exhibits dependent measurements. The mentioned approaches rely on bootstrapping or permutations in order to control the false discovery rate (FDR). However, this is was not feasible for a typical TPP experiment due to the low numbers of biological replicates. Instead, we construct an F-statistic for which we can borrow information across proteins.
In particular, we propose to estimate distribution parameters in order to approximate the χ 2 -square mixture distributions incorporated into this statistic.
Using the five published datasets introduced in Fig. 1E and Table 1 , we show that NPARC improves specificity and sensitivity compared to the established parameter-centric approach. Among these datasets, three experiments were conducted in intact cells treated by the cancer drugs panobinostat [6] or dasatinib in different concentrations [5] . Furthermore, two experiments were conducted in which cell lysates were treated with the high-affinity, ATP-competitive pan-kinase inhibitor staurosporine [5] , or with the cellular metabolite ATP [9] (see Table 1 for details).
RESULTS

2.1.
Non-parametric analysis of response curves. Our approach is based on fitting two competing models to the data, a null model and an alternative model. The null model states that the relative concentration of a protein at increasing temperatures t is explained by a single smooth function µ(t) irrespective of treatment condition and replicate ( Fig. 2A) . The deviations between data and the fitted model are referred to as residuals.
The function µ(t) is fitted to the data in such a way that the sum of squared residuals (RSS) is minimized. The alternative model replaces this common function by condition-specific functions: µ T (t) for the treatment group, and µ V (t) for the vehicle group (Fig. 2B ). It is fitted by minimizing the sum of squared residuals of the data in each group. The approach could be generalized to more complex experimental designs, as is often done in analysis of variance (ANOVA) or linear regression.
2.1.1. Hypothesis testing in a functional framework. In order to detect proteins with different melting curve shapes between treatment conditions, we construct an F-statistic that enables testing for significant improvements in goodness-of-fit of the alternative model relative to the null model (Fig. 2C) . Conceptually, the Fstatistic quantifies the relative reduction in residuals from null to alternative model. By definition, F is always positive, but for proteins not affected by the treatment, we expect values of F close to zero, whereas higher values indicate that thermostability was affected by the drug treatment. For example, as shown in Fig. 2B , serine/threonine protein kinase 4 (STK4) is strongly shifted by staurosporine treatment. Its F-statistic is among the highest ones in the dataset, as highlighted by the arrow in Fig. 2C . The F-statistic serves as base for computation of p-values and control of the false discovery rate (FDR) [24] .
2.1.2.
Choice of mean function. The mean functions µ(t), µ T (t) and µ V (t) need to be chosen from a space of smooth functions. There are various options for choosing these functions which can be conceptually divided into two categories: (1) nonparametric smooth functions that allow flexible shapes, or (2) nonlinear models that impose shape constraints based on prior knowledge. Under idealizing assumptions often made in protein thermodynamics, the thermal degradation of a protein follows a sigmoid trend [5] , and we thus parametrize the mean functions by the three-parameter equation (Fig. 3A-E) . Besides known HDACs, the strongest effects on thermostability were observed for TTC38, the histone proteins H2AFV or H2AFZ (the two variants could not be distinguished by mass spectrometry), and zinc finger FYVE domain-containing protein 28 (ZFYVE28) (Fig. 3F-H ). All these proteins have been previously identified as direct or indirect targets of panobinostat [6, 11] .
In principle, these results coincide with a T m -based ranking on the same dataset [6] . However, the advantage of NPARC becomes apparent for HDAC1 and HDAC2. For both proteins, not only the thermostability, but also the variance of the measurements appears to be affected by the treatment. This impairs the accuracy of the parameter estimates of µ T . For this reason the requirements placed on the goodness-of-fit by the T m -based approachdiscard HDAC1 and HDAC2 from the analysis regardless of their high effect sizes. Instead of relying on a single variable, T m , derived from these estimates to summarize the treatment effect, the F-test enables weighting model uncertainty against the magnitude of the effect along the whole curve. Furthermore, by including additional covariates in the alternative model, the F-statistic can accommodate more complex experimental design, such as treatments with different drug concentrations. This is illustrated by the identification of known targets of the BCR-ABL inhibitor dasatinib ( Figure S4 ).
2.3.
NPARC enables the detection of treatment effects not reflected by changes at the melting point. In the analysis of the staurosporine data, we observed several cases where treatment effects were not well reflected by T m -shifts. To assess the capability of NPARC to detect such proteins, we compared the targets detected by NPARC to those obtained by the T m -based approach (Fig. 4) .
Among the proteins only detected by NPARC, the RanGTP binding tRNA export receptor exportin-T (XPOT) exhibited the smallest T m -shift followed by two members of the p38 MAPK signaling pathway: Mitogenactivated protein kinase 14 (MAPK14) and MAP kinase-activated protein kinase 2 (MAPKAPK2). Despite a small effect size, the proteins reached statistical significance due to high reproducibility of the observation.
The advantage of NPARC is also exemplified by protein kinase C beta (PRKCB), a member of the protein kinase C (PKC) family and destabilized upon target engagement. Members of the PKC family were the first reported staurosporine targets [25, 4] . The effect is reflected by reproducible changes in curve shape before the melting point (Fig. 1C ) which can be successfully detected by NPARC. Interestingly, several other PKC members also display a destabilization prior to the T m (Fig. S5) , highlighting again that the T m is an unsuitable summary parameter for the treatment effect in this protein family. In a similar manner, NPARC is able to identify the small but reproducible shift caused by dasatinib treatment on Bruton tyrosine kinase (BTK), an important drug target in B-cell leukemia (Fig. 1B). 2.4. NPARC enables the detection of targets with missing melting point estimates. In each dataset analyzed for this work, we observed a subset of proteins for which the T m in one or both treatment conditions was outside of the tested temperature range (Fig. 1E) . One example is NAD(P)H quinone dehydrogenase 2 (NQO2), a cytosolic flavoprotein and a common off-target of kinase inhibitors [26, 27, 28] . Previous CETSA studies have described NQO2 to be highly stable [29] . This is in concordance with our data, where we observe denaturation under normal conditions only beginning at 67
• C (Fig. 1D ). Staurosporine treatment further stabilizes NQO2 to an extent that it shows no sign of melting in the tested temperature range. Theoretically, one could predict the T m by extrapolating the fitted mean functions µ T (t) and µ V (t). However, their estimates become increasingly unreliable with increasing temperatures. Instead, the curve-based comparison by NPARC allows the assessment of effects directly observed in the measured temperature range.
2.5. NPARC exhibits increased sensitivity compared to the T m -based approach . So far we have illustrated that the proposed NPARC approach allows the assessment of effects that were previously not identifiable. In order to assess whether this improves the overall performance, we compared its ability to detect targets with high specificity and sensitivity to the T m -based approach on the staurosporine data and the ATP data. For both compounds, comprehensive lists of expected targets were available based on Gene Ontology annotation (see Table 1 for details).
In both datasets, NPARC enabled the detection of more known targets for a given number of unexpected hits compared to the replicate-wise z-tests for both datasets (Fig. 5) . When applying the filters in Table 3 , the performance of the T m -based approach becomes similar to NPARC, particularly in the staurosporine dataset. Yet, NPARC exhibits a higher sensitivity than the T m -based approach while sustaining equal specificity. Additional benefits are its ability to rank protein according to effect strength and that it does not rely on excluding proteins from the test by a separate filtering step.
DISCUSSION
Thermal proteome profiling offers the possibility to comprehensively characterize ligand-protein interactions on a proteome-wide scale in living cells. However, the method poses the analytical challenge of how to identify statistically significant shifts in thermostability amongst thousands of measurements. In this work, we show that previous analytical workflows, relying on T m estimation, suffer from needless loss of sensitivity.
In particular,
we demonstrate that in the high-throughput setting of TPP experiments, T m is an insufficient summary of treatment effects. We illustrate examples of proteins whose observed melting curves are affected by drug treatment without substantially affecting the T m . In addition, we highlight cases with high thermostability for which the T m is located outside of the tested temperature range, impairing confident estimation.
In order to tackle this challenge, we introduce a functional approach to test for treatment effects. NPARC compares two competing models by their goodness-of-fit instead of testing on a single parameter. This enables detection of treatment effects for proteins where a (de-)stabilization cannot be captured by the T m . In addition, it increases the coverage of testable proteins and allows ranking of proteins by p-values without the ad hoc thresholds on which the original workflow relied [5] . Its flexibility allows adaptation to more complex experimental designs by including additional covariates, or by allowing multiple levels (e.g. drug concentrations) per covariate.
The suggested framework is also flexible with regard to the mean function used to represent the melting behavior and can be adapted to the particular biological effect of interest. For nonlinear regression problems, spline-based regression [23, 20] or nonlinear regression are most commonly employed. We choose the latter as it incorporates a priori knowledge about the data and is thus able to provide a better representation. For example, sigmoid curves require horizontal asymptotes at plateau regions. These are typically poorly represented by splines, which tend to overfit data in these regions.
In a cellular environment we occasionally observe non-sigmoid melting curves for subsets of proteins. A possible reason is the presence of protein subpopulations with distinct melting curves [13] . For example, the formation of protein complexes, the binding to other molecules, or the localization in cellular compartments can lead to deviations from the idealized sigmoid melting curve expected from the same protein in purified form.
Our model currently does not account for such systematic and reproducible shape deviations. This could be adapted in future work by adding a low-parametric systematic modification to the sigmoid mean function.
We approximate an 'average' null distribution for all proteins by estimating the DOF of the F-statistic numerator and denominator from the respective observed χ 2 -distributions. In doing so, we assume that the empirical distribution of all test statistics is an F-distribution under H 0 whose parameters are accessible by numerical optimization. Nonetheless, we could show that the current approach offers very good sensitivity and reliable and robust specificity for several example studies, including ones with a very specific and promiscuous binder.
CONCLUSIONS
We present a functional approach to compare response curves like those arising in TPP experiments. By mapping the data to a space of smooth functions and testing on these functions, it uses information from the whole curve and does not rely on further abstraction of these functions to summary parameters like melting points. This enables the detection of a wider range of treatment effects that leads to changes in curve shape, but not the estimated melting point. By these means, it makes better use of information contained in the data than the established statistical workflow and finds a larger fraction of biologically or pharmacologically relevant target proteins. The method is easy to use and all necessary parameters are derived from the data, removing the need for manual tuning. We are currently finalizing the R-package NPARC, which will soon be released as an open-source Bioconductor package. (Table 1) , a substantial fraction of proteins cannot be analysed due to failure to estimate T m -values or to meet goodness-of-fit criteria (Table 4 ). (Fig. S3) . (Table 1) . Abundance measurements per protein and temperature were extracted from the supplements of the respective publications [5, 6, 9] . All measurements were scaled per protein and replicate to the abundance at 37
• C (the lowest of the ten temperatures at which denaturation was assessed), and subjected to the global normalization procedure described by Savitski et al. [5] .
Only proteins reproducibly quantified with at least one unique peptide in the vehicle and compound treated groups of both replicates were included in the analysis (see Table 1 for the final sample sizes). 5.2. Assignment of expected targets. In order to obtain objective criteria for the comparison of test sensitivity and specificity, expected targets for the pan-kinase inhibitor staurosporine and ATP were assigned by Gene Ontology (GO) annotation, using the Bioconductor annotation packages 'AnnotationDbi' (version 1.36.2), 'org.Hs.eg.db' (version 3.4.0), and 'GO.db' (version 3.4.0). The resulting numbers of assigned targets are shown in Table 2 . 
Dataset
GO term
Proteins with GO term in dataset ATP data 'ATP-binding' 558 Staurosporine data 'protein kinase activity' 187 5.3. Mathematical model. We denote with y ijk the relative abundance measurement for protein i, temperature t j and experiment k. Each experiment can be assigned to a treatment group c (e.g. c = T for the compound-treated group and c = V for the vehicle-treated group). Each experiment yields measurements for N temperature points.
We regard the set of measurements y ik = [y i1k , y i2k , . . . y iN k ] as realizations of a stochastic process {Y ic } = {Y ic (t) : t > 0}. This process is specific for each protein and treatment group, and consists of random variables
2 defined by a treatment-specific smooth mean function µ ic (t) : [t min , t max ] → R ≥0 and a covariance function γ ic (s, t).
The covariance function defines the random fluctuation of each process realization Y ic (t) around the mean function µ ic (t). The variances γ ic (t, t) consist of measurement errors and systematic fluctuations whose extent depends non-monotonically on temperature. This is caused by the fact that the variation is higher at steep areas of the curve than at the plateaus (heteroscedasticity across temperatures).
Motivated by basic protein thermodynamics, we choose Equation (1) for the mean function. It reflects an idealized melting behavior that should well approximate a majority of proteins in the sample [30] . In this model, a, b ≥ 0 control the shape of the curve and f ∞ ∈ R ≥0 is the value that f (t) approaches for large temperatures. Similar to Storey et al. [23] , we assume the intercept to be implicitly the same in both conditions to enable direct comparison of different responses to heat-stress, independent of abundance differences at the lowest temperature. For this purpose, all measurements are scaled by f 0 = f (t min ), so that Equation (1) is parametrized by three free parameters a, b, f ∞ .
The model could be extended to fit f 0 as an additional free parameter, or by completely substituting Equation (1) by a more flexible model like smoothing splines [20] .
5.4.
Test statistic and p-value calculation. 
To account for systematic treatment effects, the alternative model replaces the common mean function µ i with condition-specific mean functions µ ic :
To assess changes in the melting curve of a protein caused by treatment, we compare the variances explained and unexplained by condition-specific modeling for this protein. We estimate these variances from the residual sums of squares of the null model (RSS 0 ) and the alternative model (RSS 1 ) and compare them by an F-statistic:
Here, the sums of squared residuals for the null and alternative model are computed by
and (6) RSS
where E is the total number of experiments, i.e. the number of all replicates in all treatment groups.
5.4.2.
Estimating the distribution under H 0 . If we could assume independently and identically normally distributed residuals, the F-statistics would be F-distributed under H 0 with DOF depending only on the numbers of measurements and parameters:
Here, p 0 is the number of parameters in the null model, and p 1 > p 0 is the number of parameters in the alternative model.
In practice, the residuals have different variances at different temperatures (heteroscedasticity) and show dependencies between consecutive temperatures, which reduces the effective DOF and leads to over-optimistic p-values when applying Equation (7). While we can still approximate the empirical distribution of F i by an F-distribution under H 0 , we have to estimate the DOF from the data. If we had a sufficiently large number of replicates for each protein, we could try to estimate the DOF separately per protein by established methods from functional data analysis like the Welch-Satterthwaite approximation [31] . However, this method requires estimation of the covariance function, which is not robust for the small sample sizes and the sparse sampling grid in a typical TPP dataset.
Instead, we make the simplifying assumption that the null distribution can be approximated reasonably well by common DOF across all proteins. To estimate them, we make use of the fact that the F-distribution is a ratio distribution with χ 2 -distributed numerator and denominator, so that:
with a global scaling parameter σ 2 0 to reflect the average variance across all proteins. The fit is performed by numerical optimization using the MASS::fitdistr function in R on the values of (RSS 0 − RSS 1 ) and RSS 1 after scaling by σ 0 . The optimization critically relies on a reasonable estimate of the scaling parameter σ 0 . This parameter is estimated from the sample mean and variance of (RSS 1 − RSS 0 ).
We define M := mean(RSS 1 − RSS 0 ) and V := Var(RSS 1 − RSS 0 ), the first moment, and the second central moment of the distribution of (RSS 1 − RSS 0 ). We then make use of the fact that the scaled χ 2 -distribution can be re-parameterized as a Γ-distribution, and that there is an established relationship between the moments of the Γ-distribution and its shape and scale parameters. We first re-parameterize the scaled χ 2 -distribution (8) as a Γ-distribution with shape parameter
and scale parameter
Making use of the relationships between the moments of the Γ-distribution and its shape and scale parameters:
and substituting (10) and (11) into (12) and (13), we obtain expressions of M and V in terms of df 1 and σ 0 :
Combining (14) and (15) , and solving for d 1 yields:
This allows to solve for the scaling factor σ 2 0 :
These equations coincide with those used by Brown's method [32] . Brown 5.5. Model fitting. All models were fitted by nonlinear least squares regression using the nls function in R.
For the NPARC analysis, the melting curve model (Eq. (1)) was fitted separately per protein to obtainμ i (t), or per protein and treatment condition to obtainμ ic (t). To reproduce the results of the T m -based approach (Table   3) , the model fits were repeated per replicate and treatment condition for each protein.
5.6. Summary of the T m -based approach. The results of the T m -based approach were obtained with the R package TPP [17] . The package is comprehensively described elsewhere [6] and will only be briefly sum- so that it fulfilled f (T m ) = 0.5. After melting curve fitting, a filtering step was applied to remove curves with undesirable shape or goodness-of-fit by setting a threshold on the R 2 , the slope and the plateau parameter (Table 4) . Within each replicate, the difference in T m of the treatment and control condition (∆T m ) was computed per protein and converted to z-scores. Robust versions of the z-scores were computed by replacing the mean and standard deviation by the corresponding quantiles of the empirical distributions of ∆T m . In order to minimize the influences of values with high estimator uncertainty when calculating these quantiles, proteins were binned by the slopes of their curves, and z-scores were calculated separately for each bin as described in [34] . Next, p-values were calculated by comparing the z-scores to the normal distribution.
To reach the final decision for each protein, the p-values were combined heuristically across replicates using the rules in Table 3 . 2 Both melting point differences are either positive or negative in the two biological replicates.
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The smallest absolute difference between treatment and vehicle T m is greater than the absolute T m difference between the two vehicle experiments. Both vehicle curves have a plateau f ∞ < 0.3.
In each biological replicate, the steepest slope of the melting curve in the vehicle and treatment group is ≤ −0.06. FIGURE S1. Experimental workflow of thermal proteome profiling (TPP) experiments for generation of the datasets listed in Table 1 .
FIGURE S2. Effects of QC-filters administered to restrict analysis to 'well-behaved' curves for hypothesis testing. 
